All AbMole products are for research use only, cannot be used for human consumption.
SY-1365 (Mevociclib) is a selective covalent CDK7 inhibitor. SY-1365 inhibited cell growth of many different cancer types at nanomolar concentrations. SY-1365 treatment decreased MCL1 protein levels, and cancer cells with low BCL-XL expression were found to be more sensitive to SY-1365. SY-1365 demonstrated substantial anti-tumor effects in multiple AML xenograft models as a single agent. SY-1365-induced growth inhibition was enhanced in combination with the BCL2 inhibitor venetoclax.
Molecular Weight | 587.12 |
Formula | C31H35ClN8O2 |
CAS Number | 1816989-16-8 |
Solubility (25°C) | DMSO 10mM |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Related CDK Products |
---|
(E/Z)-Zotiraciclib citrate
(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor. |
Abemaciclib metabolites M2
Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50 values of 1.2 and 1.3 nM, respectively. |
CDK9-IN-1
CDK9-IN-1 is a novel, selective CDK9 inhibitor, with an IC50 of 39 nM for CDK9/CycT1, it can be used for the research of HIV infection. |
XO44
XO44 (PF-6808472) is a broad-spectrum covalent kinase probe. |
ML 315
ML 315 is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.